Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies.

[1]  A. López-Guillermo,et al.  Adult haemophagocytic syndrome , 2014, The Lancet.

[2]  H. Lévesque,et al.  Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. , 2013, Joint, bone, spine : revue du rhumatisme.

[3]  M. Cottone,et al.  Systematic review: macrophage activation syndrome in inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.

[4]  J. Singh,et al.  Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. , 2013, Immunotherapy.

[5]  M. Ramos-Casals,et al.  Biologics-induced autoimmune diseases , 2013, Current opinion in rheumatology.

[6]  I. Tiong,et al.  A Case of Hemophagocytic Lymphohistiocytosis in a Patient with Chronic Lymphocytic Leukemia after Treatment with Fludarabine, Cyclophosphamide, and Rituximab Chemotherapy, with Autopsy Findings , 2012, Case reports in hematology.

[7]  B. Pozzetto,et al.  Management of cytomegalovirus infection in inflammatory bowel diseases. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[8]  K. Kasai,et al.  Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. , 2012, Cytokine.

[9]  M. Bronze,et al.  Viral Infections in Patients With Inflammatory Bowel Disease on Immunosuppressants , 2012, The American journal of the medical sciences.

[10]  W. Fries,et al.  Severe CMV-related pneumonia complicated by the hemophagocytic lymphohistiocytic (HLH) syndrome in quiescent Crohn's colitis: harmful cure? , 2011, Inflammatory bowel diseases.

[11]  X. Bosch,et al.  Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. , 2011, The American journal of medicine.

[12]  K. Theil,et al.  A rare trigger for macrophage activation syndrome , 2011, Rheumatology International.

[13]  G. Guyatt,et al.  Adverse effects of biologics: a network meta-analysis and Cochrane overview. , 2011, The Cochrane database of systematic reviews.

[14]  A. Mimori,et al.  Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome , 2011, Modern rheumatology.

[15]  R. Brouwer,et al.  Histoplasma capsulatum reactivation with haemophagocytic syndrome in a patient with chronic lymphocytic leukaemia. , 2010, The Netherlands journal of medicine.

[16]  Y. Bryceson,et al.  Alemtuzumab treatment for hemophagocytic lymphohistiocytosis , 2010, Nature Reviews Clinical Oncology.

[17]  H. Endo,et al.  Exacerbation of adult‐onset Still’s disease, possibly related to elevation of serum tumor necrosis factor‐alpha after etanercept administration , 2010, International journal of rheumatic diseases.

[18]  G. Sterba,et al.  Macrophage activation syndrome induced by etanercept in a patient with systemic sclerosis. , 2010, The Israel Medical Association journal : IMAJ.

[19]  T. Numakura,et al.  [Tuberculosis associated with hemophagocytic syndrome complicated by treatment with infliximab]. , 2010, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society.

[20]  A. Olivé,et al.  Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. , 2010, Joint, bone, spine : revue du rhumatisme.

[21]  R. Avery,et al.  A 21‐year‐old man with Still's disease with fever, rash, and pancytopenia , 2010, Arthritis care & research.

[22]  P. Pavese,et al.  Réactivation bactériémique d’une brucellose 70 ans après la primo-infection , 2010 .

[23]  M. Bobo,et al.  Haemophagocytic syndrome and paradoxical reaction to tuberculostatics after treatment with infliximab , 2010, Pharmacy World & Science.

[24]  T. Fukuda,et al.  Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus , 2010, Modern rheumatology.

[25]  J. V. van Dissel,et al.  Fever, shock, and pancytopenia in a patient treated with alemtuzumab. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  G. Salles,et al.  Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy. , 2008, Clinical lymphoma & myeloma.

[27]  M. Khamashta,et al.  Vasculitis induced by tumor necrosis factor-targeted therapies , 2008, Current rheumatology reports.

[28]  M. Ramos-Casals,et al.  A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases , 2008, Medicine.

[29]  M. Khamashta,et al.  Autoimmune diseases induced by TNF-targeted therapies. , 2008, Best practice & research. Clinical rheumatology.

[30]  F. Sylvester,et al.  Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab. , 2008, Journal of pediatric gastroenterology and nutrition.

[31]  B. Saint-Marcoux,et al.  Tocilizumab for multirefractory adult-onset Still’s disease , 2008, Annals of the rheumatic diseases.

[32]  B. Zimmermann,et al.  Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents , 2008 .

[33]  M. Kurrer,et al.  Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult‐onset Still's disease and concurrent macrophage activation syndrome , 2008, American journal of hematology/oncology.

[34]  M. Khamashta,et al.  Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases , 2007, Medicine.

[35]  M. Aricò,et al.  HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis , 2007, Pediatric blood & cancer.

[36]  P. Brastianos,et al.  Tuberculosis-associated haemophagocytic syndrome. , 2006, The Lancet. Infectious diseases.

[37]  R. Blum,et al.  Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  E. Keystone,et al.  Musculoskeletal manifestations and autoimmune diseases related to new biologic agents , 2006, Current opinion in rheumatology.

[39]  K. Neftel,et al.  Haemophagocytic syndromes in adults: current concepts and challenges ahead. , 2005, Swiss medical weekly.

[40]  É. Chauveau,et al.  Syndrome d’activation macrophagique après traitement par infliximab pour maladie de Crohn fistulisée , 2005 .

[41]  P. Emery,et al.  Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. , 2004, Arthritis and rheumatism.

[42]  A. Aouba,et al.  Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. , 2003, Rheumatology.

[43]  R. Riley,et al.  Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. , 2001, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[44]  M. Feldmann,et al.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.

[45]  R. Egeler,et al.  HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. , 1997, Medical and pediatric oncology.

[46]  A. Öst,et al.  DIAGNOSTIC GUIDELINES FOR HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS , 1991 .

[47]  G. Cormier,et al.  Macrophage activation syndrome revealing disseminated tuberculosis in a patient on infliximab. , 2013, Joint, bone, spine : revue du rhumatisme.

[48]  K. Adachi,et al.  Hemophagocytic lymphohistiocytosis in a rheumatoid arthritis patient treated with infliximab. , 2012, Internal medicine.

[49]  M. Kawano,et al.  Etanercept-induced lupus accompanied by hemophagocytic syndrome. , 2011, Internal medicine.

[50]  J. Roth,et al.  Surgery: Future directions in multimodality therapy for NSCLC , 2010, Nature Reviews Clinical Oncology.

[51]  M. Khamashta,et al.  Autoimmune diseases induced by biological agents: a double-edged sword? , 2010, Autoimmunity reviews.

[52]  R. Buckstein,et al.  Macrophage activation syndrome after etanercept treatment. , 2007, The Journal of rheumatology.